Company Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Employees

Sector

Biotechnology & Medical Research

More about the company

24-06-24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
24-05-13	Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	CI

24-06-24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
24-05-13	Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	CI
23-10-14	Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	CI
23-01-27	Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	CI
22-12-12	Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	CI
22-02-23	Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	CI
21-12-16	Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	CI
21-11-17	Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	CI
21-10-12	CombiGene in Billion-Dollar Deal with Spark Therapeutics	CI
21-09-07	NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	CI
21-07-21	Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	CI
21-04-13	Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	CI
21-02-25	Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	CI

23-04-11	One of Nature’s journals publishes article about CombiGene’s epilepsy project	AQ
23-01-30	Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	AQ
23-01-30	Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	AQ
22-05-17	Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	AQ
22-05-10	CombiGene presents at Aktiedagen Göteborg on Monday 16 May	AQ

22-12-12	Roche: Gentherapie SPK-8011 von Tochter Spark erweist sich als dauerhaft wirksam
19-12-17	Roche-Chef will aus Spark ein Exzellenzzentrum für Gentherapie machen
19-12-17	Roche exécute son offre sur Spark Therapeutics
19-12-17	Spark Therapeutics : Roche finalise son acquisition
19-12-17	Roche officialise la finalisation de la reprise de Spark Therapeutics

Manager	Title	Age	Since
Sylke Poehling CEO	Chief Executive Officer	-	2024-09-08
Michael Retterath PRN	Corporate Officer/Principal	-	2020-11-15

Spark Therapeutics Inc Stock Nasdaq

Stocks

Biotechnology & Medical Research

Latest news : Spark Therapeutics Inc

Press Releases: Spark Therapeutics Inc

News in other languages: Spark Therapeutics Inc

Managers and Directors: Spark Therapeutics Inc

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Bruce Resnick BRD	Director/Board Member	-	2019-12-16
Sean Johnston BRD	Director/Board Member	-	2019-12-16

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-3.42%	+10.05%	+58.59%	+87.70%	57.82B
ARGENX SE	-0.05%	-6.20%	+55.97%	+124.61%	53.71B
INSMED INCORPORATED	-2.14%	-7.78%	+4.46%	+421.65%	23.8B
BIONTECH SE	-0.47%	-2.11%	-17.25%	-15.41%	23.26B
WUXI BIOLOGICS (CAYMAN) INC.	-0.56%	+10.26%	+44.03%	-3.86%	20.7B
GENMAB A/S	-0.29%	-0.08%	+38.91%	-27.98%	17.81B
PHARMAESSENTIA CORPORATION	-4.55%	-8.65%	+194.32%	+349.58%	16.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.61%	+8.99%	+46.11%	+691.67%	16.36B
EXELIXIS, INC.	+0.23%	-0.77%	+26.37%	+187.16%	13.96B
Average	-1.54%	+1.05%	+50.17%	+201.68%	27.15B
Weighted average by Cap.	-1.62%	+0.18%	+49.56%	+166.57%

End-of-day quote Nasdaq Other stock markets
-	-